웹2024년 9월 20일 · Darüber hinaus erteilt Basilea SillaJen eine Sublizenz seiner Rechte und Pflichten aus dem Lizenz- und Kooperationsvertrag mit NTRC. Adesh Kaul, Chief Financial … 웹1일 전 · 신라젠(SillaJen)은 13일 식품의약품안전처로부터 TTK/PLK1 저해제 ‘BAL0891’의 국내 진행성 고형암에 대한 임상1상(NCT05768932) 임상시험계획(IND)을 승인받았다고 공시했다. …
[특징주] Silajen,
웹Basilea Announces Acquisition Of Rights For Oncology Asset BAL0891 By Sillajen And Updates Financial Guidance 웹2024년 4월 14일 · 종목 :신라젠 (4월14일 천만주 종목) ★ 시총7,046억억원 코스닥101위 ★ 최대주주 및 특수관계인 지분 엠투엔 18% 문은상 5% ★ 사업부분 :항암 바이러스 기반 … tapsoba jersey number
Clinical Trial on Advanced Solid Tumor: BAL0891, Carboplatin, …
웹2일 전 · The company is also developing intravenous injectable oncolytic vaccinia virus pipelines, SJ-600 series, to be more applicable and efficacious against various tumors. In addition, SillaJen, Inc. newly added BAL0891, a mitotic checkpoint inhibitor, as another pipeline in Oncology. The company recently started a phase 1 trial with BAL0891 in the US. 웹2024년 2월 27일 · News Summary: SillaJen Inc. said on Monday it has enrolled the first patient in a US phase 1 trial of an anti-cancer drug BAL0891 licensed from Swiss … 웹SillaJen is a privately-held biotechnology company focused on engineering and developing best-in-class oncolytic virus immunotherapeutics. ... BAL0891; SJ-600 Series; JX-900 … taps on 2nd tavern \u0026 grill